↓ Skip to main content

Heart Failure

Overview of attention for book
Cover of 'Heart Failure'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 13 Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction
  3. Altmetric Badge
    Chapter 23 Mesenchymal Stem Cell Therapy for the Treatment of Heart Failure Caused by Ischemic or Non-ischemic Cardiomyopathy: Immunosuppression and Its Implications
  4. Altmetric Badge
    Chapter 24 Heart Failure Guidelines on Pharmacotherapy
  5. Altmetric Badge
    Chapter 25 Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders
  6. Altmetric Badge
    Chapter 27 Comorbidities in Heart Failure
  7. Altmetric Badge
    Chapter 28 Vasopressin and Vasopressin Antagonists in Heart Failure
  8. Altmetric Badge
    Chapter 30 Iron Deficiency Treatment in Patients with Heart Failure
  9. Altmetric Badge
    Chapter 31 Cardiac Myosin Activation with Gene Therapy Produces Sustained Inotropic Effects and May Treat Heart Failure with Reduced Ejection Fraction
  10. Altmetric Badge
    Chapter 55 Ivabradine.
  11. Altmetric Badge
    Chapter 56 Wnt Signaling in Cardiac Remodeling and Heart Failure
  12. Altmetric Badge
    Chapter 74 Epidemiology of Heart Failure
  13. Altmetric Badge
    Chapter 75 Clinical Trial Design, Endpoints, and Regulatory Requirements
  14. Altmetric Badge
    Chapter 76 Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside
  15. Altmetric Badge
    Chapter 77 Sacubitril/Valsartan (LCZ696) in Heart Failure
  16. Altmetric Badge
    Chapter 80 Platelet-Derived Growth Factor in Heart Failure
  17. Altmetric Badge
    Chapter 81 Gene Therapy in Heart Failure
  18. Altmetric Badge
    Chapter 82 Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease
  19. Altmetric Badge
    Chapter 83 Partial Adenosine A1 Agonist in Heart Failure
  20. Altmetric Badge
    Chapter 86 Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction
  21. Altmetric Badge
    Chapter 88 New and Emerging Therapies and Targets: Beta-3 Agonists
  22. Altmetric Badge
    Chapter 99 Noncoding RNAs in Heart Failure
  23. Altmetric Badge
    Chapter 100 Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure
  24. Altmetric Badge
    Chapter 101 The Three-Decade Long Journey in Heart Failure Drug Development
  25. Altmetric Badge
    Chapter 123 Mitochondrial Therapies in Heart Failure
  26. Altmetric Badge
    Chapter 126 Anticoagulation Therapy and NOACs in Heart Failure
Attention for Chapter 80: Platelet-Derived Growth Factor in Heart Failure
Altmetric Badge

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
24 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Platelet-Derived Growth Factor in Heart Failure
Chapter number 80
Book title
Heart Failure
Published in
Handbook of experimental pharmacology, January 2016
DOI 10.1007/164_2016_80
Pubmed ID
Book ISBNs
978-3-31-959658-7, 978-3-31-959659-4
Authors

John Medamana, Richard A. Clark, Javed Butler

Abstract

Defective vascular and cardiomyocyte function are implicated in the development and progression of both heart failure with reduced and preserved ejection fraction. Any treatment option that augments these myocardial processes may therefore be of significant value. The platelet-derived growth factor (PDGF) family is involved in a wide range of growth processes and plays a key role in both regulating angiogenesis and mesenchymal cell development. Thus, PDGF may serve as a potent therapy for heart failure. While numerous animal studies have demonstrated beneficial cardiovascular effects of growth factor therapy, promising laboratory data has not yet translated to effective therapies. In this review, we outline the biological role of PDGF and summarize previous studies that have focused on the cardiovascular effects of normal PDGF signaling, administration of PDGF, and the effects of PDGF on stem cell therapy.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 24 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 4 17%
Student > Master 3 13%
Student > Ph. D. Student 3 13%
Student > Doctoral Student 2 8%
Researcher 2 8%
Other 3 13%
Unknown 7 29%
Readers by discipline Count As %
Medicine and Dentistry 6 25%
Biochemistry, Genetics and Molecular Biology 5 21%
Agricultural and Biological Sciences 2 8%
Nursing and Health Professions 1 4%
Pharmacology, Toxicology and Pharmaceutical Science 1 4%
Other 1 4%
Unknown 8 33%